Профілактика РТПХ інгібітором кальциневрину — how tacrolimus/cyclosporine quiet donor T-cells after allogeneic transplant, from mechanism to tapering.
When donor T-cells encounter recipient alloantigen, T-cell receptor engagement triggers a calcium influx that activates the phosphatase calcineurin. Calcineurin dephosphorylates NFAT (nuclear factor of activated T-cells), allowing it to enter the nucleus and switch on IL-2 and other activation genes. Tacrolimus (bound to FKBP-12) and cyclosporine (bound to cyclophilin) each form a drug–immunophilin complex that clamps onto calcineurin and blocks this dephosphorylation step — starving donor T-cells of the signal they need to proliferate and attack recipient tissue.
Acute graft-versus-host disease begins when donor T-cells recognize recipient antigens as foreign. Full activation requires three coordinated signals: TCR engagement, costimulation, and cytokine amplification. The calcium–calmodulin–calcineurin–NFAT pathway sits at the heart of the first signal cascade.
By occupying calcineurin's active site, the drug–immunophilin complex does not kill T-cells outright — it functionally silences them. Without NFAT translocation, T-cells fail to transcribe IL-2, IL-4, and interferon-gamma, so alloreactive clones cannot expand into an effector population large enough to damage skin, gut, and liver — the classic GVHD target organs.
Because the blockade is reversible and dose-dependent, clinicians can titrate the degree of immune suppression, which is the foundation for the therapeutic monitoring and tapering strategies covered in later stages.
This mechanism is shared by tacrolimus and cyclosporine but not by other GVHD prophylaxis drugs — sirolimus, for example, blocks mTOR downstream of cytokine receptors, and is used differently as a result.
Blocking calcineurin alone leaves gaps — some alloreactive clones escape suppression, particularly early after transplant when donor lymphocyte numbers are highest. Combining a calcineurin inhibitor with a second, mechanistically distinct agent closes those gaps and is now the standard-of-care backbone for most allogeneic transplant regimens.
Methotrexate is a folate antagonist: it blocks dihydrofolate reductase, starving rapidly dividing donor lymphocytes of the nucleotides they need to proliferate. Given as a short pulse in the first two weeks after transplant, it blunts the initial wave of alloreactive expansion while the calcineurin inhibitor maintains a steadier, longer-acting suppression of activation signaling.
Mycophenolate mofetil works differently again — it inhibits inosine monophosphate dehydrogenase, an enzyme lymphocytes depend on more heavily than most other cell types for purine synthesis. MMF is often favored over methotrexate in reduced-intensity or umbilical cord blood transplants because it carries less mucositis and myelosuppression risk.
In both pairings, the calcineurin inhibitor remains the backbone drug, typically continued for months, while the partner agent is used for a shorter, more intensive early window.
Calcineurin inhibitors have one of the narrowest therapeutic windows in transplant medicine. Levels too low leave donor T-cells free to attack recipient tissue; levels too high accelerate nephrotoxicity and neurotoxicity. Regular trough blood draws are the only reliable way to keep patients inside the target band, especially given how much individual drug metabolism varies.
Unlike drugs with a wide safety margin, calcineurin inhibitors show steep dose-response curves for both efficacy and toxicity, and absorption/metabolism vary enormously between patients — driven by gut motility, diarrhea from conditioning regimens, liver function, and genetic polymorphisms in CYP3A metabolizing enzymes.
A trough level drawn immediately before the next scheduled dose approximates steady-state exposure. Levels below the target band correlate with breakthrough acute GVHD; levels above it correlate with acute kidney injury, tremor, and posterior reversible encephalopathy syndrome (PRES). Because the same numeric level can mean different things depending on the specific assay and transplant protocol, targets are set locally by each program rather than being a single universal number.
Drug interactions are a major hazard: azole antifungals and certain calcium channel blockers inhibit the same CYP3A pathway that clears calcineurin inhibitors, and can double or triple blood levels within days if doses are not preemptively adjusted.
The same vasoconstrictive and calcineurin-blocking properties that suppress alloreactive T-cells also stress the kidneys, nervous system, and metabolic pathways. Nephrotoxicity is the most consequential and best-studied risk, but it does not act alone — clinicians track a broader toxicity panel for the full duration of prophylaxis.
Calcineurin inhibitors constrict the afferent arteriole feeding the glomerulus, reducing renal blood flow. Acutely this is reversible and dose-dependent, but sustained exposure over months can produce structural changes — interstitial fibrosis and arteriolar hyalinosis — that are not fully reversible even after the drug is stopped. Because early nephrotoxicity is often asymptomatic, serum creatinine and estimated GFR are checked on a recurring schedule alongside every trough level draw.
Neurotoxicity ranges from mild tremor and headache — common and usually tolerable — to rarer but serious posterior reversible encephalopathy syndrome, which can present with seizures or visual disturbance and generally improves once the drug is reduced or held.
Metabolic effects include new-onset hypertension (very common, often needs antihypertensive therapy), hyperkalemia, hypomagnesemia, and increased risk of post-transplant diabetes. None of these toxicities are usually severe enough alone to stop prophylaxis, but together they are the reason calcineurin inhibitor courses are monitored as closely as the GVHD risk they are meant to prevent.
Toxicity monitoring and efficacy monitoring share the same blood draw: a single trough level, read alongside creatinine and blood pressure, informs both the GVHD-risk side and the toxicity-risk side of the dosing decision.
GVHD risk is highest in the first few months after transplant and declines as donor and recipient immune systems establish tolerance. Calcineurin inhibitor doses are tapered accordingly — slowly enough that withdrawal itself does not unmask alloreactivity, but steadily enough to limit the cumulative toxicity burden of many months of therapy.
Tapering is not simply stopping a drug — it is a controlled experiment in immune tolerance. Most protocols hold a stable, full-dose prophylaxis level through the highest-risk window (commonly the first three to six months), then begin reducing the dose in small increments, often every one to two weeks, while watching closely for any new skin rash, liver enzyme rise, or gastrointestinal symptoms that might signal emerging GVHD.
Patients who remain GVHD-free through a gradual taper are gradually approaching graft-versus-host tolerance: donor immune cells increasingly recognize recipient tissue as self, or are actively regulated by donor regulatory T-cells, without needing pharmacologic suppression. Patients who flare during taper typically have their dose increased back to the last tolerated level and the schedule extended.
Tapering too quickly risks triggering rebound acute or chronic GVHD; tapering too slowly prolongs exposure to nephrotoxicity, infection risk, and metabolic side effects. The pace is therefore individualized, guided by chimerism results, ongoing organ function, and whether any GVHD symptoms have appeared.